Strategies to Mitigate the Rising Cancer Cost Burden



Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs. 

Transcript

If you’re looking at it from a payer’s perspective, we see payers really paying a lot of attention to the oncology space, particularly self-administered oncology, looking at the criteria of use for those. You look at CML. Now we have patients who are living longer. This has become a chronic disease for these patients. So we see some specialty generics coming to space, imatinib for CML. You see some benefits across the entire space with overall cost of therapy with these specialty generics.



Most Popular

Related Articles

Top news of the day from across the health care industry.
Eric Dallara, RPh, pharmacist for the New England Cancer Specialists explains the current challenges in the industry, especially regarding payment plans and payment reform during the National Community Oncology Dispensing Association, Inc. in Denver, Colorado.
The shift from fee-based, volume-driven care to value-based, patient-centered care and the growth of specialty pharmaceuticals are propelling us all into uncharted territory, no matter what role you play in health care.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$